Dey Ipratropium Reprint Warning Not In Conflict With WLF Ruling, FDA Says
Executive Summary
A warning letter issued by FDA regarding implied superiority claims by Dey Labs in a journal reprint disseminated for its generic ipratropium is consistent with the recent Washington Legal Foundation ruling, FDA maintained.